Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Vincent Rajkumar

Showing results (471-480 of 566) with videos related to

Pageof 57
Sort By:
Blood Cancer Journal|December 3, 2021
Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentageCarlos Fernández de Larrea, Robert Kyle, Laura Rosiñol, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 31, 2021
The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Cross-analysis of a Population-based Registry and a Tertiary Care CenterLaura A Evans, Ronald Go, Rahma Warsame, et al.
Bone Marrow Transplantation|December 23, 2017
Impact of prior melphalan exposure on stem cell collection in light chain amyloidosisSurbhi Sidana, Nidhi Tandon, Morie A Gertz, et al.
Blood|January 7, 2006
Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantationAngela Dispenzieri, Martha Q Lacy, Jerry A Katzmann, et al.
Blood Advances|November 23, 2018
Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myelomaMohammed A Aljama, M Hasib Sidiqi, Arjun Lakshman, et al.
British Journal of Haematology|July 13, 2019
Ten-year survivors in AL amyloidosis: characteristics and treatment patternEli Muchtar, Morie A Gertz, Martha Q Lacy, et al.
Blood Cancer Journal|February 18, 2025
Clonal plasma cell proportion in the synthetic phase identifies a unique high-risk cohort in multiple myelomaSaurabh Zanwar, Dragan Jevremovic, Prashant Kapoor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 24, 2024
Simplified Risk Stratification Model for Patients With Waldenström MacroglobulinemiaSaurabh Zanwar, Jennifer Le-Rademacher, Eric Durot, et al.
Blood|March 31, 2011
International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantationMichele Cavo, S Vincent Rajkumar, Antonio Palumbo, et al.
Blood|July 15, 2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myelomaPaul G Richardson, Emily Blood, Constantine S Mitsiades, et al.
Pageof 57

Showing results (471-480 of 566) with videos related to

Sort By:
Pageof 57
Blood Cancer Journal|December 3, 2021
Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentageCarlos Fernández de Larrea, Robert Kyle, Laura Rosiñol, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 31, 2021
The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Cross-analysis of a Population-based Registry and a Tertiary Care CenterLaura A Evans, Ronald Go, Rahma Warsame, et al.
Bone Marrow Transplantation|December 23, 2017
Impact of prior melphalan exposure on stem cell collection in light chain amyloidosisSurbhi Sidana, Nidhi Tandon, Morie A Gertz, et al.
Blood|January 7, 2006
Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantationAngela Dispenzieri, Martha Q Lacy, Jerry A Katzmann, et al.
Blood Advances|November 23, 2018
Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myelomaMohammed A Aljama, M Hasib Sidiqi, Arjun Lakshman, et al.
British Journal of Haematology|July 13, 2019
Ten-year survivors in AL amyloidosis: characteristics and treatment patternEli Muchtar, Morie A Gertz, Martha Q Lacy, et al.
Blood Cancer Journal|February 18, 2025
Clonal plasma cell proportion in the synthetic phase identifies a unique high-risk cohort in multiple myelomaSaurabh Zanwar, Dragan Jevremovic, Prashant Kapoor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 24, 2024
Simplified Risk Stratification Model for Patients With Waldenström MacroglobulinemiaSaurabh Zanwar, Jennifer Le-Rademacher, Eric Durot, et al.
Blood|March 31, 2011
International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantationMichele Cavo, S Vincent Rajkumar, Antonio Palumbo, et al.
Blood|July 15, 2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myelomaPaul G Richardson, Emily Blood, Constantine S Mitsiades, et al.
Pageof 57